Abstract:Hepatocellular carcinoma (HCC), one of the most fatal malignancies in the world, is usually diagnosed in advanced stages due to late symptom manifestation with very limited therapeutic options, which leads to ineffective intervention and dismal prognosis. For a decade, tyrosine kinase inhibitors (TKIs) have offered an overall survival (OS) benefit when used in a first-line (sorafenib and lenvatinib) and second-line setting (regorafenib and cabozantinib) in advanced HCC, while long-term response remains unsatisfactory due to the onset of primary or acquired resistance. Recently, immunotherapy has emerged as a promising therapy in the treatment of several solid tumors, such as melanoma and non-small cell lung cancer. Moreover, as the occurrence of HCC is associated with immune tolerance and immunosurveillance escape, there is a potent rationale for employing immunotherapy in HCC. However, immunotherapy monotherapy, mainly including immune checkpoint inhibitors (ICIs) that target checkpoints programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and the cytotoxic T lymphocyte antigen-4 (CTLA-4), has a relatively low response rate. Thus, the multi-ICIs or the combination of immunotherapy with other therapies, like antiangiogenic drugs and locoregional therapies, has become a novel strategy to treat HCC. Combining different ICIs may have a synergistical effect attributed to the complementary effects of the two immune checkpoint pathways (CTLA-4 and PD-1/PD-L1 pathways). The incorporation of antiangiogenic drugs in ICIs can enhance antitumor immune responses via synergistically regulating the vasculature and the immune microenvironment of tumor. In addition, locoregional treatments can improve antitumor immunity by releasing the neoplasm antigens from killed tumor cells; in turn, this antitumor immune response can be intensified by immunotherapy. Therefore, the combination of locoregional treatments and immunotherapy may achieve greater efficacy through further synergistic effects for advanced HCC. This review aims to summarize the currently reported results and ongoing trials of the ICIs-based combination therapies for HCC to explore the rational combination strategies and further improve the survival of patients with HCC.

Strategies for Improving the Efficacy of Immunotherapy in Hepatocellular Carcinoma

Immunotherapy of Hepatocellular Carcinoma: Recent Progress and New Strategy.

Heterogeneous Responses in Hepatocellular Carcinoma: the Achilles Heel of Immune Checkpoint Inhibitors.

Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma

Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials

Immunotherapies for advanced hepatocellular carcinoma

Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma

Improving the Efficacy of Liver Cancer Immunotherapy: the Power of Combined Preclinical and Clinical Studies

Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects

Combined Immunotherapy for Hepatocellular Carcinoma: How to Maximize Immune Checkpoint Blockade Synergic Anti-tumor Effect

Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives

Immunotherapy of Hepatocellular Carcinoma: Strategies for Combinatorial Intervention

Recent advances in immunotherapy for hepatocellular carcinoma

Immunotherapies for hepatocellular carcinoma

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects

Advances in Immune Checkpoint Therapy in Hepatocellular Carcinoma

Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future

Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy

Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.

Trends in the Treatment of Advanced Hepatocellular Carcinoma: Immune Checkpoint Blockade Immunotherapy and Related Combination Therapies.

Current Perspectives of Immunotherapy for Hepatocellular Carcinoma.